Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF (Rebalance-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04592445
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : September 17, 2021
Sponsor:
Information provided by (Responsible Party):
Axon Therapies, Inc.

Brief Summary:
The objective of this clinical evaluation is to assess the safety and initial effectiveness of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in subjects having heart failure with preserved ejection fraction (HFpEF).

Condition or disease Intervention/treatment Phase
Heart Failure With Preserved Ejection Fraction Device: Satera GSN Ablation Device: Sham Control Not Applicable

Detailed Description:

This clinical investigation is a prospective, multi-center randomized, sham control, double blinded feasibility clinical study. Both the subject and the noninvasive cardiologist that is caring for the subject will be blinded to the assigned cohort (treatment or sham). The interventional cardiologist who performs the index procedure will not be blinded.

Subjects who meet the eligibility criteria and are enrolled will be randomized 1:1 to either ablation of the right GSN using the Axon System (treatment cohort) or sham (control cohort) at the time of the procedure.

This study will enroll up to 100 subjects at an anticipated 20 US sites. Subject follow up is at 1, 3, 6, and 12 months

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects randomized 1:1 (treatment to sham control); no cross over
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Subject and HF Cardiologist providing care are blinded. Interventionalist who performs the Index procedure in not
Primary Purpose: Treatment
Official Title: ENDOVASCULAR ABLATION OF THE RIGHT GREATER SPLANCHNIC NERVE IN Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having HFpEF: Feasibility Study: Randomized Controlled Feasibility Trial- Rebalance HF Study
Actual Study Start Date : December 18, 2020
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Active Comparator: Axon Treatment Arm
Subjects will receive treatment with the Satera Ablation System following administration of anesthesia access to the R GSN and ablation of the GSN at 1-2 levels will occur.
Device: Satera GSN Ablation
The Axon procedure consists of a small needle puncture made in the groin to pass standard sheaths, wires, and access devices into the femoral vein, using standard access methods. The right GSN will be ablated transvenously from the right intercostal veins where it crosses at the 10th and 11th thoracic vertebrae from the intercostal vein intersection with the azygos vein. Placement of the access devices and Axon catheter is confirmed using standard fluoroscopic imaging. Once positioning is confirmed, GSN ablation can commence accordingly .

Sham Comparator: Sham Control Arm
Following administration of anesthesia subjects will have femoral vein access only. Procedure choreography to mimic procedure steps and length.
Device: Sham Control
The sham procedure consists of a small needle puncture made in the groin to pass a standard femoral introducer sheath approximately 10 cm into the femoral vein, using standard access methods. The Axon Catheter and associated access accessories will not be inserted into the patient. The sham procedure duration will be similar to the treatment time for subject receiving the Axon therapy (~30 minutes).




Primary Outcome Measures :
  1. Primary Outcome Endpoint [ Time Frame: 1 Month ]
    Change in mean PCWP at 1 month follow up evaluated as a repeated measure at rest, legs up and exercise (20W) as compared to the baseline PCWP evaluation. This reduction will be assessed in all subjects (both treated and control) to explore mechanism of action

  2. Primary Safety Outcome [ Time Frame: 1 month ]
    Evaluation of device or procedure-related serious adverse events at 1-month follow up based on Clinical Events Committee (CEC) assessment.


Secondary Outcome Measures :
  1. Secondary Outcome Endpoints [ Time Frame: 1, 3, 6, and 12 months ]
    * Quality of Life: Change in KCCQ score evaluated over time from baseline and 1, 3, 6, and 12-months follow up.

  2. Secondary Outcome Endpoints [ Time Frame: 1, 3, 6, and 12 months ]
    *Change in 6MWT distance evaluated over time from baseline and 1, 3, 6, and 12 months follow up.

  3. Secondary Outcome Endpoints [ Time Frame: 1, 3, 6, and 12 months ]
    *Incidence of heart failure hospitalization through 12 months

  4. Secondary Outcome Endpoints [ Time Frame: 1 month ]
    *Reduction in PCWP at 1 month follow up at rest, legs up, exercise at 20W and peak exercise as compared to the baseline PCWP evaluation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects ≥ 40 years of age
  2. Chronic heart failure defined as at least one of the following:

    1. Symptoms of HF requiring current treatment with diuretics for > 30 days, AND
    2. NYHA class II with a history of > NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening; or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND
    3. > 1 HF hospital admission (with HF as the primary, or secondary diagnosis);

      • OR - treatment with intravenous (IV) diuretics, or intensification of oral diuresis for HF in a healthcare facility within the 12 months prior to study entry;
      • OR - NT-pro BNP value > 150 pg/ml in normal sinus rhythm, > 450 pg/ml in atrial fibrillation within the past 6 months;
      • OR - BNP value > 50 pg/ml in normal sinus rhythm, > 150 pg/ml in atrial fibrillation within the past 6 months.
  3. Ongoing stable GDMT HF management and management of potential comorbidities according to the 2017 ACCF/AHA Guideline for the Management of Heart Failure, with no significant changes [>100% increase or 50% decrease] for a minimum of 1 month prior to screening, that is expected to be maintained without change for at least 3 months.
  4. LVEF > 50 % (site determined by TTE) in the past 3 months.
  5. Site determined elevated PCWP documented by right heart catheterization by PCWP ≥ 25 mmHg during supine ergometer exercise

    a. PCWP to be evaluated by a Swan Ganz procedure performed either prior to the day of the index procedure or on the day of the index procedure

  6. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

Exclusion Criteria:

  1. MI (type I) and/or percutaneous cardiac intervention within past 3 months; CABG in past 3 months, or current indication for coronary revascularization.
  2. Cardiac Resynchronization Therapy initiated within the past 3 months.
  3. Advanced heart failure defined as one or more of the below:

    1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF
    2. Cardiac index < 2.0 L/min/m2
    3. Inotropic infusion (continuous or intermittent) for LV EF< 30% within the past 6 months
    4. Subject is on the cardiac transplant waiting list
  4. BMI > 45 kg/m2
  5. Inability to perform 6-minute walk test (distance < 100 meters), OR ability to perform 6-minute walk test distance > 450 meters.
  6. Admission for HF within the 30 days prior to planned index procedure.
  7. In the last 3 years no ejection fraction (EF) below 40
  8. Systolic BP < 100 mmHg or > 170 mmHg despite appropriate medical management.
  9. No evidence of orthostatic hypotension; defined as systolic blood pressure decrease of >20mmHg and/or increase in heart rate >20 bpm upon going from supine to standing position or requiring any treatment for orthostatic hypotension
  10. Arterial oxygen saturation < 90 % on room air.
  11. Presence of significant valve disease defined by the site cardiologist as:

    1. Mitral valve stenosis defined as <1.5 cm2 (or greater than mild)
    2. Mitral valve regurgitation defined as grade > 3+ MR
    3. Tricuspid valve regurgitation defined as grade > 3+ TR
    4. Aortic valve disease defined as > 3+ AR or > severe AS
  12. Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis)
  13. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel.
  14. Mean resting right atrial pressure (RAP) > 20 mmHg based upon screening right heart catheterization.
  15. History of severe liver cirrhosis
  16. Dialysis dependent; or estimated-GFR <25 ml/min/1.73 m2 by MDRD equation.
  17. Baseline status of persistent atrial fibrillation with resting HR >100 beats per minute that could obfuscate RHC interpretation.
  18. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation (including intubations) in the 12 months before study entry OR known history of GOLD Class II or higher COPD.
  19. Currently participating in conflicting investigational drug or device study.
  20. Life expectancy <12 months for non-cardiovascular reasons.
  21. Any condition, or history of illness or surgery that, in the opinion of the Investigator, might confound the results of the study or pose additional risks to the patient.
  22. Females who are not pregnant or lactating and not or planning to become pregnant for the duration of the studyduring the next year.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04592445


Contacts
Layout table for location contacts
Contact: Sierra Yearsley 16508670927 s.yearsley@axontherapies.com

Locations
Show Show 18 study locations
Sponsors and Collaborators
Axon Therapies, Inc.
Layout table for additonal information
Responsible Party: Axon Therapies, Inc.
ClinicalTrials.gov Identifier: NCT04592445    
Other Study ID Numbers: 09868
First Posted: October 19, 2020    Key Record Dates
Last Update Posted: September 17, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases